Docetaxel trihydrate - polymorphous studies and the new useful method to obtaining one of polymorph.

Witold S. Cieśliński 1Andrzej Ostrowski 2

1. IFOTAM Co. Ltd (IFOTAM), Andrzejewskiej 3, Łódź 92-550, Poland
2. Warsaw University of Technology, Faculty of Chemistry, Noakowskiego 3, Warszawa 00-664, Poland

Abstract

Docetaxel is an antineoplastic agent belonging to the taxoid family and is available on the market in the injection form under the brand name Taxotere®, containing docetaxel trihydrate as an active pharmaceutical ingredient (API). Docetaxel trihydrate  crystallizes in two different forms, namely in form A and form B. Both forms have been disclosed by L.Zaske & col. [1], [2]. Their structure dates are available in Cambride Structure Database (code CSD: DARGOT & DARGOT01). The crystalografic data and Cambride Structure Datebase data of both docetaxel trihydrate crystal forms were not fulfilled. They include the space group information and unit cell parameters only.

The aims of this work were:

  1. Fully identification of docetaxel trihydrate crystal forms by methods use in  the polymorphs studies, such as: Termogravimetric Analysis (TGA), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FT-IR), X-Ray Powder Diffraction (XRPD),
  2. The research of new methods of obtaining of docetaxel trihydrate.

The standards of docetaxel trihydrate form A and B  have been obtained and identified. TGA date, DSC date, FT-IR characteristic peaks, and XRPD 2theta angels are shown.

The new preparation method of docetaxel trihydrate, form A, was a subject of our further research. The method is based on crystallization of docetaxel from 2-etoxyethanol and water mixture and is especially useful in docetaxel isolation and purification. As result of the direct docetaxel’s separation from reaction mixture, the product is obtained without decomposition and in course of a simple procedure. The isolated product has a purity of not less than 98%, depending on the starting purity of the employed substrate, and can be further purified by crystallization only.

The presented preparation-method of the docetaxel trihydrate, form A, is subject of Polish Patent application no. P-388498.

References:

[1] L.Zaske, M.-A.Perrin, F.Laveiller J.Phys. IV France 11(2001) Pr10-221;

[2] L.Zaske, M.-A.Perrin, C.Daiguebonne, O.Guillou, Materials Science Forum vols. 443-444 (2004); pp 411-0

 

Legal notice
  • Legal notice:

    Copyright (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: http://science24.com/paper/23154 must be provided.

 

Related papers
  1. The new solvates of docetaxel and C2-C3 alkyl esters of formic acid and their use for API’s preparation.
  2. Synthesis of gallium nitride nanowires by Sublimation Sandwich Method
  3. Synthesis of aluminum nitride nanopowder; compare methods for determination of the grain size in nanopowders 
  4. SYNTHESIS AND CYTOTOXIC ACTIVITY OF 10-DEACETYL-10-PROPARGILPACLITAXEL

Presentation: Poster at VII Multidyscyplinarna Konferencja Nauki o Leku, by Witold S. Cieśliński
See On-line Journal of VII Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2010-04-19 15:43
Revised:   2010-04-20 20:24